Key Performance
More- Earnings Score: 37
- Momentum Score: 75
- True Yield: N/A
- Financial Health Score: 55
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A Canadian health coalition has called on Ontario's Health Minister to halt Quest Diagnostics' transfer of laboratory testing services from Ontario hospitals to U.S.-based facilities. The coalition argues that the transfers, which began in April 2026, compromise patient privacy, reduce hospital efficiency, delay results, and divert healthcare funding to the United States. They are demanding the government cancel Quest's contract and restore lab services to public hospital control.
06/15/2026, 4:00 PM • GlobeNewswire
Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics announced a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record as of July 8, 2026. The diagnostic information services leader serves half of U.S. physicians and hospitals and one in three American adults annually.
05/19/2026, 4:37 PM • Benzinga
The global HPV testing and Pap test market is projected to grow from USD 3.7 billion in 2025 to USD 6.5 billion by 2034, driven by rising cervical cancer prevalence, government screening initiatives, technological advancements, and the introduction of self-sampling tests. North America leads the market with 40.5% share, while Asia-Pacific emerges as a key growth hub.
05/12/2026, 1:00 PM • GlobeNewswire
The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.
04/03/2026, 3:15 AM • GlobeNewswire
The global genomics services market is expected to grow from USD 7.94 billion in 2025 to USD 25.18 billion by 2035, with a CAGR of 11.8%. Growth is driven by increasing genetic disorder prevalence, government-funded precision medicine initiatives, and rising adoption of NGS-based diagnostics. The U.S. market alone is projected to reach USD 10.04 billion by 2035. Next-generation sequencing dominates with 38.42% market share, while Asia Pacific shows the fastest growth at 13.84% CAGR.
03/05/2026, 4:36 AM • GlobeNewswire
Quest Diagnostics announced a 7.5% increase in its quarterly dividend to $0.86 per share, marking 15 consecutive years of dividend increases. The company also increased its share repurchase authorization by $1 billion, bringing total available repurchase authority to approximately $1.4 billion.
02/10/2026, 6:33 AM • Benzinga
S&P 500 Earnings Halfway Mark: Sector Winners, Losers, and What Comes Next
With 59% of S&P 500 companies reported, Q4 2025 shows 13% EPS growth and 8.8% revenue growth. Big Tech's massive capex spending on AI infrastructure ($185B for Alphabet, $200B for Amazon) has sparked concerns about free cash flow sustainability and SaaS disruption from AI agents. This week's earnings focus shifts to semiconductor and software companies to assess whether AI spending benefits the broader ecosystem or threatens traditional business models.
02/09/2026, 10:48 AM • Investing
A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.
02/03/2026, 8:00 AM • GlobeNewswire
The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.
01/30/2026, 4:57 AM • GlobeNewswire
A consumer analysis examines how Taurus Medical, Inc. operates its telehealth TRT platform, which connects patients with licensed healthcare providers through OpenLoop Healthcare Partners. The analysis details the regulatory framework for testosterone as a Schedule III controlled substance, the three-entity operational structure (platform, providers, pharmacies), laboratory testing partnerships with LabCorp and Quest Diagnostics, and treatment options including injectable testosterone and enclomiphene. The article emphasizes that no prescription is guaranteed and that clinical decisions rest solely with independent licensed clinicians.
01/12/2026, 7:02 PM • GlobeNewswire
The global Non-Invasive Prenatal Testing (NIPT) market is projected to grow at a CAGR of 17.01% from 2024 to 2031, reaching USD 9.83 billion from USD 2.8 billion in 2024. Growth is driven by rising demand for early fetal detection, advancements in next-generation sequencing technology, and increased adoption of safer prenatal testing methods. However, high costs, regulatory hurdles, and limited insurance coverage remain significant market restraints, particularly in emerging markets.
01/09/2026, 10:53 AM • GlobeNewswire
The global autism spectrum disorder diagnostics market is projected to grow from $27.38 billion in 2024 to $43.36 billion by 2034, with a CAGR of 4.7%. Key growth drivers include increasing healthcare expenditure, R&D investments, and government initiatives. The autistic disorder segment will dominate at 52.82% market share, while early intervention services and online pharmacies emerge as fastest-growing segments. Major players include LabCorp, Illumina, and Bio-Rad Laboratories, with Asia Pacific and Western Europe expected to lead regional growth.
01/08/2026, 4:51 AM • GlobeNewswire
Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics announced a quarterly cash dividend of $0.80 per share, payable on January 28, 2026 to shareholders of record on January 13, 2026.
11/11/2025, 4:22 PM • Benzinga
Global fertility test market projected to grow from $7.92 billion in 2025 to $14.74 billion in 2033, driven by lifestyle changes, delayed pregnancies, and increasing infertility rates worldwide.
10/21/2025, 10:00 AM • GlobeNewswire
U.S. Drug Screening Market Size to Envision USD 3.84 Billion by 2034
The U.S. drug screening market is projected to grow from USD 2.70 billion in 2024 to USD 3.84 billion by 2034, with a 3.64% CAGR, driven by rising substance abuse, technological advances, and stringent government regulations.
10/20/2025, 12:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.